Bio-Techne Corp. TECH recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value ...

Chicago, for ‘The Bear,’ is depicted — accurately — as a place where the goal is not necessarily to win status or acclaim so ...

(RTTNews) - Bio-Techne (TECH), a US-based biotechnology company Thursday has introduced an expanded range of human and mouse RNAscope in situ hybridization probes to support spatial biology ...

Baird R W lowered shares of Bio-Techne (NASDAQ:TECH – Free Report) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports. Several other research ...

Bio-Techne Stock Performance Shares of NASDAQ TECH opened at $64.92 on Friday. The firm has a market capitalization of $10.26 billion, a price-to-earnings ratio of 65.58, a PEG ratio of 2.89 and a ...

Feb 5 (Reuters) - Bio-Techne (TECH.O), opens new tab beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop ...

KeyBanc raised the firm’s price target on Bio-Techne (TECH) to $90 from $80 and keeps an Overweight rating on the shares. Overall, fiscal Q2 ...

MINNEAPOLIS, Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope ...

Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral ...

近期，Bio-Techne Corp（NASDAQ:TECH）董事Amy E. Herr进行了一笔股票交易。在2025年2月14日，她以平均每股$65.96的价格出售了总值$122,690的股票。此次交易后，Herr在公司的直接持股量为1,040股。根据 InvestingPro 数据显示，该公司股票目前接近52周低点$61.16，分析师给出的目标价区间为$75至$95。